FluoroPharma Medical, Inc. is a molecular imaging company focused on the development and commercialization of next-generation diagnostic imaging agents for cardiovascular disease. The company’s core mission is to improve the detection and management of coronary artery disease (CAD) through precision positron emission tomography (PET) tracers that offer high resolution and quantitative assessment of myocardial perfusion and metabolism. Headquartered in Burlington, Massachusetts, FluoroPharma leverages expertise in radiochemistry, cardiology, and clinical trial execution to advance its pipeline from preclinical research through regulatory approval.
The company’s lead candidates include PET tracers designed to visualize blood flow and mitochondrial function in the heart. One agent, CardioPET™ (18F-BFPET), targets myocardial perfusion and has demonstrated favorable imaging characteristics in early clinical studies. A second tracer in development aims to assess cellular metabolism and viability, providing complementary information to perfusion imaging. These agents are labeled with fluorine-18, a radioisotope that offers a practical half-life for distribution to imaging centers and compatibility with existing PET scanner infrastructure. FluoroPharma holds multiple patents covering its proprietary synthesis methods and molecular designs.
FluoroPharma collaborates with leading academic medical centers and contract research organizations to conduct multi-site clinical trials. The company’s strategy includes pursuing regulatory clearances in the United States and Europe, followed by partnerships with diagnostic imaging networks and hospital systems to facilitate rapid adoption. In addition to cardiovascular applications, FluoroPharma is exploring broader indications where precise measurement of tissue perfusion and metabolism can enhance patient care, such as oncology and neurology.
Guided by an experienced management team with backgrounds in radiopharmaceutical development, clinical cardiology, and regulatory affairs, FluoroPharma emphasizes rigorous clinical validation and quality manufacturing practices. The company’s leadership comprises professionals who have held senior roles at major pharmaceutical firms, academic research institutions, and specialized imaging companies. As FluoroPharma advances its pivotal trials and regulatory filings, it remains committed to delivering innovative diagnostic tools that enable earlier intervention and improved outcomes for patients with heart disease.
AI Generated. May Contain Errors.